All In MedTech

Device Trial Radar · NCT06497998

EGG Sensor for Oocyte Characterization

Use of the EGG Sensor to Characterize Human Oocytes in IVF With ICSI

Last checked: Nov 19, 2026Latest source record: Jul 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Sep 2024

Primary completion

Sep 2027

Study completion Sep 2027

Sponsor

Lead sponsor
Centre Hospitalier Universitaire de BesanconAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 12, 2024

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Other
FDA-regulated device
No
Who can join
Female only, from 18 years, up to 43 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

While intracytoplasmic sperm injection (ICSI) has made significant progress in the treatment of male infertility, the cumulative delivery rate is less than 30%, and birth is sometimes only achieved after several transfers. This success rate, combined with the possibility of repeated transfer failures, causes great distress, impacting couples' personal, social, and professional lives. These failures also have a significant economic impact on society and assisted reproductive technologies (ART) laboratories, including costs related to personnel, consumables, and cryopreservation activities. Among the factors influencing the success of ICSI, the quality of the oocyte is paramount. Identifying mature oocytes with high birth potential is therefore a crucial step in any attempt. At present, oocyte selection is mainly based on subjective visual morphological criteria, primarily limited to the stage of meiotic maturation. Various objective selection criteria are currently being tested, such as markers in follicular fluid or the transcriptome of cumulus and granulosa cells. Mechanical oocyte characterization is another objective approach to assessing oocyte quality. EGG Sensor is a reliable, cost-effective platform that measures forces ranging from a few nanonewtons to a few micronewtons in a liquid medium on living cells. It enables the characterization of the mechanical behavior of oocytes (kinetic measurements of forces resulting from EGG sensor action). The EGG sensor has been evaluated, enabling the EGG platform to be duplicated at the ART center of the Besançon University Hospital, making measurement and calibration more reliable, and allowing for the characterization of a series of oocytes excluded from the ICSI procedure. The preclinical stages in the development of the EGG sensor have thus been validated. The next stage of development is to validate the device in an operational environment. The aim of this pilot study is to evaluate the mechanical qualification of oocytes by the EGG sensor in real-life conditions during an ICSI-type ART attempt.

Conditions

  • Infertility

Interventions

  • Mechanical characterizationDevice

    The oocyte is placed in a culture dish with IVF culture medium. This procedure is similar to that used in the ICSI procedure, except that the injection pipette is replaced by a glass indenter. The indenter (sterile, single-use, blunt-edged glass cylinder, L:16mm, ø:0.85mm, mass:8mg) is completely decoupled from the micromanipulation and microinjection platform and driven by the principle of a magnetic spring with negative stiffness. The oocyte is immobilized using a restraining pipette to prevent unwanted movement during measurement. The main objective is to investigate the prognostic value of parameters derived from kinetic measurements of microforces on mature human oocytes in the context of IVF with ICSI. On each oocyte the mechanical testing is divided in 4 successive loading unloading phase to measure: * global elasticity of the oocyte. * global viscosity behaviour of the oocyte. * local elasticity of the oocyte. * local viscosity behaviour of the pellucid membrane.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Differences in the global elasticity of the oocyte depending on whether or not it results in a live birth.Time frame: 36 months
  2. Differences in the global viscosity behaviour of the oocyte depending on whether or not it results in a live birthTime frame: 36 months
  3. Differences in the local elasticity of the oocyte depending on whether or not it results in a live birthTime frame: 36 months

1 more outcomes with a free account

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.